In collaboration with Fox Chase Cancer Center, we have initiated a program focused on developing PDX models in various cancer indications. These indications include but are not limited to pancreatic, renal, esophageal, gastric, colon, rectal, breast, lung carcinomas, lymphoma, and many others. The following information is available for all our established models; patient information, including stage/grade, age, gender, race, and tumor growth curves. For most of these tumor models, we also have information on adjuvant and neo-adjuvant treatments and patients responses. All initial specimens in our model collection have been developed predominantly from patients of Caucasian ethnicity.

The majority of models are accompanied by Whole Exome Sequence and RNA Seq data, oncogene panel sequences, microarray analysis of gene expression, as well as some limited information on xeno-trials in mice. We are more than happy to discuss the possibility of sharing with you our models on a non-exclusive basis. In addition, our broad IRB protocol with Fox Chase Cancer Center allows us to implant any type of tumor. We would be happy to implant models that are of particular interest to you.


  • SOP 1

    BRF identifies and consents the patient prior to surgery

  • SOP 2

    BRF delivers a slip and transport vial

  • SOP 3

    Freshly obtained tumor sample placed in media

  • SOP 4


    • BRF number assigned

    • If not placed in the OR, a sterile 1cm3 tumor sample within 20 minutes in cold transport media

    • Pathologist releases the BRF sample if deemed “residual” from clincial care

  • SOP 5
    SOP 5
    SOP 5

    BioSample Repository

    Provides sample for PDX implantation

    Tumor tissue Processed

    • Paraffin fixed

    • Frozen

    • Tumor and blood DNA

    Clinical Information